Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

189406 Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem

189406
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

Empirical FormulaCAS #
C₁₅H₁₂F₂N₆O₃S • CH₃CN 443797-96-4

Products

Número de referenciaEmbalaje Cant./Env.
189406-5MG Ampolla de plást. 5 mg
Description
OverviewA cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).
Catalogue Number189406
Brand Family Calbiochem®
Synonyms4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, Aurora Kinase Inhibitor I, JNJ-7706621
References
ReferencesEmanuel, S., et al. 2005. Cancer Res. 65, 9038.
Lin R., et al. 2005. J. Med. Chem. 48, 4208.
Product Information
CAS number443797-96-4
ATP CompetitiveY
FormWhite solid
Hill FormulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
Chemical formulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
ReversibleY
Structure formula ImageStructure formula Image
Applications
Biological Information
Primary TargetAurora Kinase/Cdk
Primary Target IC<sub>50</sub>11 and 15 nM for Aurora-A, Aurora-B, respectively; 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively
Purity≥97% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Harmful
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem Certificados de análisis

CargoNúmero de lote
189406

Referencias bibliográficas

Visión general referencias
Emanuel, S., et al. 2005. Cancer Res. 65, 9038.
Lin R., et al. 2005. J. Med. Chem. 48, 4208.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision17-April-2008 RFH
Synonyms4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, Aurora Kinase Inhibitor I, JNJ-7706621
DescriptionA cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number443797-96-4
Chemical formulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
Structure formulaStructure formula
Purity≥97% by HPLC
SolubilityDMSO (15 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Harmful
ReferencesEmanuel, S., et al. 2005. Cancer Res. 65, 9038.
Lin R., et al. 2005. J. Med. Chem. 48, 4208.